Ibis Capital Partners
VC Fund
Tokyo, Japan
Ibis Capital Partners is an investment banking firm focused on M&A advisory, management consulting.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Ibis Capital Partners invests in
Stages Ibis Capital Partners invests in
Countries Ibis Capital Partners invests in
Investment Focus
Industry
- Logistics 2 (40%)
- Artificial Intelligence 2 (40%)
- GPU 1 (20%)
- Medical 1 (20%)
- Internet 1 (20%)
Stage
- Funding Round 3 (60%)
- Post-IPO Equity 1 (20%)
- Venture - Series Unknown 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Yamato Holdings
|
Yamato Holdings mainly provides door-to-door parcel delivery services. The company has developed a nationwide delivery system specializing in time-specified delivery. Yamato Holdings offers moving services and other comprehensive transportation services including logistics services for both domestic and overseas customers as well as financial andautoworks services. | Post-IPO Equity / Feb 18, 2020 | |
YAMATO
|
YAMATO develops and provides AI services for financial sector. | Venture - Series Unknown / Feb 18, 2020 | |
ALI Technologies
|
Aerial Lab Industries focuses on research and development of UAV (unmanned miniature aircraft). | $12.6M / May 22, 2018 | |
AI CROSS
|
AI CROSS is an internet company that uses artificial intelligence (AI) to help enterprises communicate through mobile with their customers. AI CROSS is also a leading messaging service provider in Japan – The company has been providing 2-way SMS service since SMS interconnection between carriers has started here. It offers carrier directconnection to all major carriers in Japan. Combining its high-quality route with our expertise in messaging in Japan, they've got range of customers including SMS aggregators, app providers, finance, HR, and so on. AOS Mobile is headquartered in Tokyo, Japan. | $42.5M / Nov 28, 2017 | |
BrightPath Biotherapeutics
|
BrightPath Biotherapeutics is a stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company develops products based on peptide vaccine technology that stimulates a potent immune response to tumor-associated antigens. | $170.1M / Aug 29, 2014 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Ibis Capital Partners invest in?
Ibis Capital Partners invests primarily in Logistics, Artificial Intelligence and GPU startups, most often at Funding Round and Post-IPO Equity stage. Most of the 5 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Ibis Capital Partners last invest?
The most recent investment recorded for Ibis Capital Partners closed in Feb 2020. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
